RCM
RNAC icon

RA Capital Management’s Cartesian Therapeutics RNAC Stock Holding History

RA Capital Management’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-3,167
Closed -$270K – 73
2020
Q2 		$270K Sell
3,167
-25,854
-89% -$2.34M 0.01% 57
2020
Q1 		$2.1M Buy
+29,021
New +$2.8M 0.07% 46

Other funds holding RNAC

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
MWNA
Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return
PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return

RA Capital Management's RNAC Position: Q3 2020 in Review

RA Capital Management sold out of Cartesian Therapeutics (RNAC) in Q3 2020, closing a stake of 3,167 shares — an estimated $270K sold.

RA Capital Management first reported a position in RNAC in Q1 2020 and held it in 2 quarters. The position peaked at $2.1M in Q1 2020. 79 funds tracked by Wall St. Rank hold RNAC as of Q3 2020.

  • RA Capital Management reported no remaining Cartesian Therapeutics position as of Q3 2020 after selling out during the quarter.
  • RA Capital Management sold 3,167 Cartesian Therapeutics shares in Q3 2020, an estimated $270K.
  • RA Capital Management first reported a position in Cartesian Therapeutics in Q1 2020 and held it in 2 quarters.
  • RA Capital Management's Cartesian Therapeutics position peaked at $2.1M in Q1 2020.
  • 79 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q3 2020.

Based on RA Capital Management's 13F filing for Q3 2020, filed 16 Nov 2020.